ALDX NASDAQ
Aldeyra The
1W: -3.3%
1M: -21.5%
3M: -48.7%
YTD: -75.0%
1Y: -77.7%
3Y: -80.8%
5Y: -86.2%
$1.17
-0.12 (-9.30%)
Weekly Expected Move ±13.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.36
Bullish
3 bullish
1 neutral
1 bearish
Articles (7d)
5
Daily Sentiment (7 Days)
Articles (100)
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
Aldeyra plans FDA dispute request for reproxalap
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
Aldeyra Therapeutics to appeal FDA rejection of dry eye disease drug reproxalap
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
Vertex Posts Positive Phase II Data on Kidney Disease Drug
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
Definium Reports Second Phase III Success in Anxiety Disorder Program
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
1,257,243 Shares in Aldeyra Therapeutics, Inc. $ALDX Purchased by BlackRock Inc.
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
Here's Why You Should Add RNTX Stock to Your Portfolio Now
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down
LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
Here's Why You Should Add ARQT Stock to Your Portfolio Now
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
Levicept appoints Darlene Deptula-Hicks as CFO
12 Health Care Stocks Moving In Friday's After-Market Session
ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, P.C. Urgently Reminds Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
ALDX FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm – ALDX
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX Deadline Alert: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After FDA Issued A CRL Indicating Insufficient Efficacy: Levi & Korsinsky
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026
ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Disregarded FDA Requirements: Levi & Korsinsky
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
ALDX Shareholder Alert: May 29, 2026 Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. Securities Class Action - Contact The Gross Law Firm
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Aldeyra Therapeutics Investors - Contact Kirby McInerney LLP by May 29, 2026
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Down 14.6% in March
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
ALDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aldeyra Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm
ROSEN, A LEADING AND RANKED FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
ADLX Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aldeyra Therapeutics, Inc. Class Action Lawsuit
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. (ALDX)
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Aldeyra Therapeutics, Inc. (ALDX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Sees Large Increase in Short Interest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Aldeyra Therapeutics (NASDAQ:ALDX) Director Buys $98,000.00 in Stock
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
FY2026 Earnings Forecast for ALDX Issued By HC Wainwright
12 Health Care Stocks Moving In Thursday's Intraday Session
What's Going On With Aldeyra Therapeutics Stock On Thursday?
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX)